Article Text

Download PDFPDF

Carcinomatous meningitis: antibody-guided therapy with I-131 HMFG1.
  1. R P Moseley,
  2. J C Benjamin,
  3. R D Ashpole,
  4. N M Sullivan,
  5. J A Bullimore,
  6. H B Coakham,
  7. J T Kemshead
  1. Frenchay Hospital, Bristol, UK.


    Seven patients with carcinomatous meningitis were administered intrathecal I-131 labelled monoclonal antibody HMFG1. Clinical responses were seen in two patients, with a long term survivor at 32 months. Aseptic meningitis occurred in 4/7 patients, but more serious toxicity was observed in the form of seizures (2/7 patients) and myelosuppression (3/7 patients). Partial obliteration of the subarachnoid space was identified as a potential problem in patients with advanced disease.

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.